<DOC>
	<DOCNO>NCT00193440</DOCNO>
	<brief_summary>In trial , evaluate feasibility , toxicity , effectiveness ibritumomab tiuxetan , incorporate combination first-line treatment follicular lymphoma . Addition ibritumomab tiuxetan previously evaluate , well tolerate combination rituximab short course chemotherapy allow use additional active agent unique mechanism cytotoxicity . In addition , `` debulking '' lymphoma prior 90Y Zevalin administration may minimize myelotoxicity agent .</brief_summary>
	<brief_title>Rituximab Chemotherapy Followed Ibritumomab Tiuxetan Treatment Low Grade Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - Rituxan + CHOP CVP + Ibritumomab Tiuxetan Patients consider medical candidate doxorubicin receive CHOP chemotherapy ( Cyclophosphamide , doxorubicin , vincristine prednisone ) . Patients consider medical candidate doxorubicin receive CVP chemotherapy ( Cyclophosphamide , Vincristine , prednisone )</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>To include study , must meet following criterion : Histologic documentation follicular center , Bcell lymphoma Early stage lymphoma ( stage I II ) relapse radiation therapy alone No previous chemotherapy monoclonal antibody therapy Measurable evaluable disease Able perform activity daily live minimal assistance Age &gt; 18 year Adequate bone marrow , liver kidney function Must accessible treatment followup . Bone marrow examination initial stag accurate restaging All patient must give write informed consent prior study entry . You participate study follow apply : Small lymphocytic ( CLL type ) lymphomas CLL Impaired bone marrow reserve Female pregnant lactate Serious active infection time treatment Any serious underlying condition Central nervous system involvement ( brain meningeal ) HIV AIDSrelated lymphoma Received prior external beam radiation therapy &gt; 25 % active bone marrow Pleural effusion Received prior murine antibody proteins History neoplasm within five year diagnosis Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>